Sign in

    Samuel N. Hazen

    Chief Executive Officer at HCA Healthcare Inc
    Since January 1, 2019
    Age
    64 years
    Tenure
    Has served in various key leadership roles at HCA for 40 years, progressing from CFO roles to President of Operations, COO, and ultimately CEO.

    Also at HCA Healthcare Inc

    CFW
    Christopher F. Wyatt
    SVP and Controller
    JLB
    Jennifer L. Berres
    SVP and Chief Human Resources Officer
    JMF
    Jon M. Foster
    EVP and Chief Operating Officer

    About

    Samuel N. Hazen has spent 40 years at HCA, demonstrating a long-standing commitment to the company through multiple leadership positions over the decades.

    Over his tenure, he advanced from pivotal financial roles—including positions as Chief Financial Officer for the Western Group—to significant operational leadership roles as President of Operations and Chief Operating Officer, which laid the groundwork for his rise to the top executive position.

    He assumed the role of Chief Executive Officer on 01-01-2019, marking a milestone where his extensive industry experience and operational expertise began driving the strategic direction of HCA.

    Although details about his personal background and education are not available, his career progression and leadership at HCA highlight his deep industry knowledge and significant contributions to shaping the company’s patient-centered mission and ethical practices.

    $HCA Performance Under Samuel N. Hazen

    Past Roles

    OrganizationRoleDate RangeDetails
    HCA President and Chief Operating Officer November 2016 - December 2018 Former role held prior to CEO appointment
    HCA Chief Operating Officer January 2015 - November 2016 Former role held prior to CEO appointment
    HCA President – Operations 2011 - 2015 Former role held prior to CEO appointment
    HCA President – Western Group 2001 - 2011 Former role held prior to CEO appointment
    HCA Chief Financial Officer – Western Group 1995 - 2001 Former role held prior to CEO appointment
    Humana Inc. and Galen Health Care, Inc. Various CFO Positions Prior to 1995 Held various hospital, regional, and division CFO positions before joining HCA

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,512,222 AnnualFixed base pay for 2023
    HCA 401(k) Plan Contributions$22,500 AnnualContributions made under the HCA 401(k) Plan
    HCA Restoration Plan Contributions$0 AnnualNo contributions for 2023
    Supplemental Executive Retirement Plan (SERP)$37,269,576 Lump SumActual lump sum value for 2023
    Accrued Vacation Pay$209,385 AccruedVacation accrual for 2023
    Health and Welfare Benefits$25,051 AnnualHealth and welfare-related benefits
    Life Insurance Benefits$1,513,000 Lump Sum on deathPayment upon death while actively employed; includes company-paid life insurance
    All Other Compensation$577,418 AnnualIncludes Dividend Equivalent Payments on Vested 2021 PSUs ($514,566 ), Matching Charitable Contributions ($35,000 ), Personal Use of Company Aircraft ($5,352 )

    Performance Compensation

    Data from  FY 2023

    Non-Equity Incentive Plan (PEP)

    MetricDetails
    WeightFinancial Performance: 80% ; Quality & Care Performance: 20%
    Performance MetricEBITDA for Financial Performance; Healthcare-Associated Infections, Sepsis, Risk-Adjusted Mortality, Complications, and Patient Experience for Quality & Care
    ThresholdEBITDA: 4% below target (25% payout) ; Quality: Performance at the 45th percentile yields 0% payout
    TargetEBITDA: $12.457B target ; Quality: 55th percentile for 100% payout
    Maximum (Cap)EBITDA: 4% above target yielding 200% payout ; Quality: 65th percentile for 200% payout
    Actual Performance & PayoutEBITDA: Achieved $13.171B (105.74% of target) resulting in 200% payout ; Quality portion achieved a payout of 177.55%, leading to an overall PEP payout of 195.51%
    Vesting ScheduleNot applicable; awards are paid out after completion of the 2023 performance period
    Evaluation PeriodFiscal year 2023 (Quality metrics measured from Q4 2022 through Q3 2023)
    Cash Payout$5,026,128
    PEP Target as % of Base Salary170%

    Equity Incentive Plan Awards (PSUs)

    MetricDetails
    Performance MetricCumulative diluted EPS for fiscal years 2023–2025
    Threshold90% of target EPS resulting in 6,866 PSUs vest (25% vesting)
    Target100% of target EPS resulting in 27,467 PSUs vest
    Maximum110%+ of target EPS with up to 54,934 PSUs vest (200% payout)
    Grant DateJanuary 30, 2023
    Grant Date Fair Value$6,957,391
    Grant Date Stock Price$253.30 per share
    Vesting SchedulePSUs vest at the end of fiscal year 2025, contingent on meeting the cumulative EPS target